Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

A careful reassessment of anthracycline use in curable breast cancer

Research output: Contribution to journalReviewResearchpeer-review

  1. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    Research output: Contribution to journalReviewResearchpeer-review

  2. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. A catalog of curated breast cancer genes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. DBCG Kvalitetsdatabase for Brystkræft – resumé af årsrapport 2020

    Research output: Contribution to journalJournal articleCommunication

  3. Socioeconomic position and prognosis in premenopausal breast cancer: a population-based cohort study in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Sara Alsterlind Hurvitz
  • Nicholas P McAndrew
  • Aditya Bardia
  • Michael F Press
  • Mark Pegram
  • John P Crown
  • Peter A Fasching
  • Bent Ejlertsen
  • Eric H Yang
  • John A Glaspy
  • Dennis J Slamon
View graph of relations

It has been over three decades since anthracyclines took their place as the standard chemotherapy backbone for breast cancer in the curative setting. Though the efficacy of anthracycline chemotherapy is not debatable, potentially life-threatening and long-term risks accompany this class of agents, leading some to question their widespread use, especially when newer agents with improved therapeutic indices have become available. Critically assessing when to incorporate an anthracycline is made more relevant in an era where molecular classification is enabling not only the development of biologically targeted therapeutics but also is improving the ability to better select those who would benefit from cytotoxic agents. This comprehensive analysis will present the problem of overtreatment in early-stage breast cancer, review evidence supporting the use of anthracyclines in the pre-taxane era, analyze comparative trials evaluating taxanes with or without anthracyclines in biologically unselected and selected patient populations, and explore published work aimed at defining anthracycline-sensitive tumor types.

Original languageEnglish
Article number134
JournalCurrent Medical Literature. Breast Cancer
Volume7
Issue number1
Pages (from-to)134
ISSN2374-4677
DOIs
Publication statusPublished - 8 Oct 2021

Bibliographical note

© 2021. The Author(s).

ID: 68605024